Attractions in Asia Pacific In Vitro Diagnostic Market for Japanese Investors in 2019-2022 - A Comparative analysis of key Asian markets (India, China, Australia and Indonesia)
With the existing tension between US and China (two major economies), it is imperative that Japanese and Korean manufacturers look at this scenario as an opportunity and enter the American IVD market in 2019. While the market is huge in north America, south and central America holds high potential.
From an investor’s perspective, the report showcases the import and export trends from 2014 and how the market might perform in 2020. From the competition perspective, it compares the presence of local and global companies in various segments such as immune-chemistry, molecular biology, microbiology, point of care testing, hematology, etc. At a regional level, the report looks at the regulations, demands and attraction in each segment i.e. market forecast in immunology, molecular biology, microbiology, POCT and at the same time looks at the consumption market i.e. hospital labs, bedside consumption in hospital, home users, research labs, etc. From the manufacturer’s perspective the report looks at the trends in equipment and reagents market country wise and region wise and gives insights on the gaps that exist in consumption markets such as Australia, Indonesia, India and China.
The market is expected to grow at a CAGR of 7% between 2019-2025. Connected Labs/ Digital Pathology is expected to be the highest growing segment at 11.8%. Unlike west, Molecular diagnostics and immune-chemistry will be more attractive than POCT (adoption rate is slow). The market has been segmented based on import/exports, competition, technology, therapeutic areas, products and services and end user.
Report 4: Attractions in the Liquid Biopsy Market – Global
The global cancer burden is estimated to have risen to 18.1 million new cases and 9.6 million deaths in 2018. One in 5 men and one in 6 women worldwide develop cancer during their lifetime, and one in 8 men and one in 11 women die from the disease. The five-year survival rate is estimated to be 43.8 million.
The proportions of cancer deaths in Asia (57.3%) are higher than the proportions of incident cases (48.4%), because APAC compared to US and Europe, has a higher frequency of certain cancer types associated with poorer prognosis and higher mortality rates, in addition to limited access to timely diagnosis and treatment in many countries.
The market is expected to grow to 35.50 Billion USD by 2025 growing at a CAGR of 12.57%, globally. Screening and profiling sub segment are expected to have the highest market share. The report gives insights on the screening technologies, regulations and deep dives into areas such as companion diagnostics, type of sample used, end user, etc.
From an investor’s perspective, the report showcases the import and export trends from 2014 and how the market might perform in 2020. From the competition perspective, it compares the presence of local and global companies in various segments such as immune-chemistry, molecular biology, microbiology, point of care testing, hematology, etc. At a regional level, the report looks at the regulations, demands and attraction in each segment i.e. market forecast in immunology, molecular biology, microbiology, POCT and at the same time looks at the consumption market i.e. hospital labs, bedside consumption in hospital, home users, research labs, etc. From the manufacturer’s perspective the report looks at the trends in equipment and reagents market country wise and region wise and gives insights on the gaps that exist in consumption markets such as Australia, Indonesia, India and China.
The market is expected to grow at a CAGR of 7% between 2019-2025. Connected Labs/ Digital Pathology is expected to be the highest growing segment at 11.8%. Unlike west, Molecular diagnostics and immune-chemistry will be more attractive than POCT (adoption rate is slow). The market has been segmented based on import/exports, competition, technology, therapeutic areas, products and services and end user.
Report 4: Attractions in the Liquid Biopsy Market – Global
The global cancer burden is estimated to have risen to 18.1 million new cases and 9.6 million deaths in 2018. One in 5 men and one in 6 women worldwide develop cancer during their lifetime, and one in 8 men and one in 11 women die from the disease. The five-year survival rate is estimated to be 43.8 million.
The proportions of cancer deaths in Asia (57.3%) are higher than the proportions of incident cases (48.4%), because APAC compared to US and Europe, has a higher frequency of certain cancer types associated with poorer prognosis and higher mortality rates, in addition to limited access to timely diagnosis and treatment in many countries.
The market is expected to grow to 35.50 Billion USD by 2025 growing at a CAGR of 12.57%, globally. Screening and profiling sub segment are expected to have the highest market share. The report gives insights on the screening technologies, regulations and deep dives into areas such as companion diagnostics, type of sample used, end user, etc.
1. ASSUMPTIONS FOR PRIMARY/SECONDARY RESEARCH
2. CURRENCY EXCHANGE RATES
3. ABBREVIATIONS
4. INTRODUCTION – APAC IVD MARKET
5. RECENT TRENDS
6. DRIVERS AND RESTRAINTS
7. SWOT ANALYSIS
8. SEGMENTATION OF THE APAC IVD MARKET
a. By Technology (Clinical Chemistry, Microbiology, Hematology, urology, Molecular Biology, Others)
b. By Products (equipment, reagents, Others)
c. By Application Area (By Disease Types)
d. By End User
9. COMPETITION TRENDS
10. APAC IVD MARKET BY REGION
a. China IVD Market
i. Segmentation by Technology
ii. Segmentation by Products
iii. Segmentation by Application Area
iv. Segmentation by End Users
v. Segmentation by Domestic Competition
vi. Regulations in China
b. Japan IVD Market
i. Segmentation by Technology
ii. Segmentation by Products
iii. Segmentation by Application Area
iv. Segmentation by End Users
v. Segmentation by Domestic Competition
vi. Regulations in Japan
c. India IVD Market
i. Segmentation by Technology
ii. Segmentation by Products
iii. Segmentation by Application Area
iv. Segmentation by End Users
v. Segmentation by Domestic Competition
vi. Regulations in India
d. Other Potential IVD Market
i. Australia IVD Market
11. KEY RECOMMENDATIONS
12. APPENDIX
2. CURRENCY EXCHANGE RATES
3. ABBREVIATIONS
4. INTRODUCTION – APAC IVD MARKET
5. RECENT TRENDS
6. DRIVERS AND RESTRAINTS
7. SWOT ANALYSIS
8. SEGMENTATION OF THE APAC IVD MARKET
a. By Technology (Clinical Chemistry, Microbiology, Hematology, urology, Molecular Biology, Others)
b. By Products (equipment, reagents, Others)
c. By Application Area (By Disease Types)
d. By End User
9. COMPETITION TRENDS
10. APAC IVD MARKET BY REGION
a. China IVD Market
i. Segmentation by Technology
ii. Segmentation by Products
iii. Segmentation by Application Area
iv. Segmentation by End Users
v. Segmentation by Domestic Competition
vi. Regulations in China
b. Japan IVD Market
i. Segmentation by Technology
ii. Segmentation by Products
iii. Segmentation by Application Area
iv. Segmentation by End Users
v. Segmentation by Domestic Competition
vi. Regulations in Japan
c. India IVD Market
i. Segmentation by Technology
ii. Segmentation by Products
iii. Segmentation by Application Area
iv. Segmentation by End Users
v. Segmentation by Domestic Competition
vi. Regulations in India
d. Other Potential IVD Market
i. Australia IVD Market
11. KEY RECOMMENDATIONS
12. APPENDIX
